Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study
Headache: The Journal of Head and Face Pain,  Clinical Article

Derosier F et al. – This study primarily included subjects whose migraines significantly impacted their lives. Before the study, these subjects used butalbital–containing medications as part of their current migraine treatment regimen and were satisfied with it, suggesting they were butalbital responders who had found a workable treatment strategy for themselves. When treated with SumaRT/Nap versus BCM in this study, however, a significant proportion of subjects reported better treatment outcomes for themselves for both migraine pain and associated symptoms. Use of SumaRT/Nap was also associated with less rescue medication use and a longer time before use of rescue medication compared with both BCM and placebo.

Methods
  • Enrolled subjects were required to have treated at least 1 migraine with a butalbital medication in the past.
  • Enrolled subjects treated 3 moderate to severe migraines using each of the 3 study treatments once in a randomized sequence.
  • The primary endpoint compared SumaRT/Nap versus BCM for sustained pain freedom at 2–24 hours without the use of any rescue medication.
  • This study combines data from 2 identical outpatient, randomized, multicenter, double–blind, double–dummy, 3 attack crossover studies in adult migraineurs (International Classification of Headache Disorders, 2nd edition).

Results
  • A total of 442 subjects treated at least 1 attack with study medication.
  • The majority of the treated subjects were female (88%) with a mean age 43 years, who reported that their migraines had a severe impact on their lives (78% with Headache Impact Test–6 of >59).
  • At screening, 88% of subjects reported current butalbital use; 68% had used butalbital for more than 6 weeks; and 82% reported satisfaction with butalbital.
  • Across treatment groups, 28–29% of subjects took study medication within 15 minutes of migraine onset, 34–37% of subjects took study medication >15 minutes to 2 hours after onset, and 32–36% of subjects took study medication more than 2 hours after onset.
  • This study did not detect a difference at the nominal 0.05 level in percent sustained pain–free between SumaRT/Nap (8%), BCM (6%), and placebo (3%).
  • SumaRT/Nap was superior to BCM for pain free at 2, 4, 6, 8, 24, 48 hours (P ≤ .044); pain relief (mild or no pain) at 2, 4, 6, 8, 24, 48 hours (P ≤ .01); sustained pain relief 2–24 hours (P < .001); migraine free (pain free with no nausea, photophobia, or phonophobia) at 4, 6, 8, 24, 48 hours (P ≤ .046); and complete symptom free (migraine free with no neck/sinus pain) at 4, 6, 8, 48 hours (P ≤ .031).
  • Adverse event incidence was similar for all treatments (10%, 12%, and 9% for placebo, SumaRT/Nap, and BCM, respectively).
  • Nausea was the most frequent adverse event (2%, 2%, and <1% for placebo, SumaRT/Nap, and BCM, respectively).
  • Five serious adverse events were reported by 3 subjects: viral meningitis and colon neoplasm (placebo); chest pain and hypertension 17 days postdose (SumaRT/Nap); and breast cancer (BCM).
  • Investigators judged no serious adverse events related to study medication.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Neurology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Neurology Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial The Lancet, October 17, 2014    Evidence Based Medicine    Clinical Article
Exclusive Author Commentary

3 Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: A multi-stage, randomised, double-blind, placebo-controlled trial The Lancet Neurology, October 9, 2014    Clinical Article

4 Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial Cerebrovascular Diseases, October 16, 2014    Clinical Article

5 Dairy products and the risk of stroke and coronary heart disease: the Rotterdam Study European Journal of Nutrition, October 14, 2014    Clinical Article

6 Hyperhomocysteinemia and risk of cognitive decline: a meta-analysis of prospective cohort studies European Neurology, October 17, 2014    Review Article

7 Intracranial hemorrhage risk with the new oral anticoagulants: A systematic review and meta-analysis Journal of Neurology, September 2, 2014    Evidence Based Medicine    Review Article

8 Patent foramen ovale closure versus medical therapy for stroke prevention: meta analysis of randomized trials and review of heterogeneity in meta analyses Canadian Journal of Cardiology, August 7, 2014    Evidence Based Medicine    Review Article    Clinical Article

9 Consumption of nuts and legumes and risk of stroke: a meta-analysis of prospective cohort studies Nutrition, Metabolism & Cardiovascular Diseases, July 28, 2014    Evidence Based Medicine    Clinical Article

10 Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial The Lancet Neurology, October 27, 2014    Evidence Based Medicine    Clinical Article

11 Antiepileptics in migraine prophylaxis: An updated Cochrane review Cephalalgia, August 14, 2014    Clinical Article

12 The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT) The Lancet, October 30, 2014    Evidence Based Medicine    Clinical Article

13 Circulating biomarkers of dairy fat and risk of incident stroke in US men and women in 2 large prospective cohorts American Journal of Clinical Nutrition, October 1, 2014    Clinical Article

14 Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study American Journal of Medicine, September 29, 2014    Clinical Article

15 Antiplatelet strategies for secondary prevention of stroke and TIA Current Atherosclerosis Reports, September 11, 2014    Review Article

16 Management of high-grade gliomas in the elderly Seminars in Radiation Oncology, October 6, 2014    Clinical Article

17 Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial European Heart Journal, September 17, 2014    Clinical Article

18 Long-term outcomes after combined revascularization surgery in adult moyamoya disease Stroke, October 8, 2014    Evidence Based Medicine    Clinical Article

19 Oral anticoagulants for stroke prevention in atrial fibrillation Current Problems in Cardiology, September 23, 2014    Review Article

20 Potassium intake and risk of stroke in women with hypertension and nonhypertension in the women’s health initiative Stroke, September 24, 2014    Clinical Article

Indexed Journals in Neurology: Current Opinion in Neurology, Stroke, Seizure, Cephalgia, Brain Injurymore